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TO THE EDITOR
Associated treatment with pegylated interferon plus specifi c antivirals signifi cantly improved the 
prognosis of chronic hepatitis C and B,1 although these drugs (especially interferon and its de-
rivatives) tend to be myelotoxic. Some rescue treatments, like human recombinant granulocyte 
colony-stimulating factors (which are extensively administered in order to correct neutropenia 
induced by antiviral therapy), may also be involved in prompting or exacerbating cutaneous pso-
riasis and its systemic complications. 
A representative case report is the one of a woman with chronic, progressive, hepatitis C, who 
underwent long-term treatment with combined pegylated interferon plus ribavirin, and resorted 
to multiple cycles of fi lgrastim to recover from a severe and recurring granulocytopenia caused 
by antiviral therapy itself and to maintain an effective dosage of anti-HCV antivirals. The patient 
developed an extensive and severe cutaneous psoriasis, which improved only after specifi c cy-
closporin treatment. 
From a pathogenetic point of view, in our case it remains extremely diffi cult to distinguish 
the role of pegylated interferon from that of the accompanying ribavirin and from that of the fre-
quently administered granulocyte growth factor (fi lgrastim), since all forementioned drugs were 
administered concurrently over several months. According to evidence from the existing litera-
ture, all of these drugs have the potential to induce psoriasis as an untoward effect in subjects suf-
fering from chronic hepatitis. Cyclosporin treatment induced a stable remission of this last severe 
cutaneous complication, but the efforts to contain the progression of the underlying hepatitis C 
were blunted by the diffi cult-to-treat genotype 1 HCV infection, and the frequent need to lower 
drug dosages and/or to interrupt antiviral therapy, because of myelotoxic and later cutaneous 
complications prompted by anti-HCV therapy itself. With regard to the management of psoriasis 
in these special hosts, the dermatologist needs to be involved in order to obtain an early diagnosis, 
to consider differential diagnoses of HCV-infected patients receiving multiple pharmacological 
treatments and with non-infrequent co-morbidities (i.e. HIV disease), and to monitor patients 
over treatment and over time.2 Also in HCV-infected patients with a newly recognized psoriasis 
or with an exacerbating psoriasic disease, cyclosporin seems a suitable treatment, with times and 
modes of delivery tailored on every single patient and disease presentation and evolution, as re-
cently commented.3 However, novel-generation compounds (like etanercept) are also expected 
to play a role in the future, since they act on the activated component of TNF-alpha, which may 
have a remarkable role in the pathogenesis and treatment of HCV disease itself, complicated by 
psoriasis.4 
[Braz J Infect Dis 2010;14(4):327]©Elsevier Editora Ltda.
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